Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer – The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29)-Reference-Cited by-同舟云学术

Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer – The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29)

Published:2016-09 Issue: Volume:64 Page:12-21
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

von Minckwitz G.,Rezai M.,Tesch H.,Huober J.,Gerber B.,Zahm D.M.,Hilfrich J.,Costa S.D.,Dubsky P.,Blohmer J.U.,Denkert C.,Hanusch C.,Jackisch C.,Kümmel S.,Fasching P.A.,Schneeweiss A.,Paepke S.,Untch M.,Burchardi N.,Mehta K.,Loibl S.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference19 articles.

1. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer;Kaufmann;Ann Surg Oncol,2012

2. Definition and impact of pathological complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes;von Minckwitz;J Clin Oncol,2012

3. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27;Rastogi;J Clin Oncol,2008

4. Future directions of bone-targeted therapy for metastatic breast cancer;Onishi;Nat Rev Clin Oncol,2010

5. Reduction in new metastases in breast cancer with adjuvant clodronate treatment;Diel;N Engl J Med,1998

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bone-modifying agents for reducing bone loss in women with early and locally advanced breast cancer: a network meta-analysis;Cochrane Database of Systematic Reviews;2024-07-09

2. Racial and Ethnic Disparities in European Breast Cancer Clinical Trials;Cancers;2024-04-29

3. Chemoinformatics and machine learning techniques to identify novel inhibitors of the lemur tyrosine kinase-3 receptor involved in breast cancer;Frontiers in Molecular Biosciences;2024-04-04

4. Benefit of adjuvant bisphosphonates in early breast cancer treated with contemporary systemic therapy: A meta-analysis of randomized control trials;Heliyon;2024-01

5. Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatment;Expert Review of Anticancer Therapy;2023-05-31